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Abstract
Hughes-Stovin Syndrome (HSS) is a very rare clinical disorder characterized by thrombophlebitis and multiple
pulmonary and/or bronchial aneurysms. Less than 40 published cases of HSS have been described in English
medical literature so far. The exact etiology and pathogenesis of HSS is unknown; possible causes include
infections and angiodysplasia. HSS has also been considered as a variant of Behcet’s disease (BD). Patients with HSS
usually present with cough, dyspnea, fever, chest pain and haemoptysis. The management of HSS can either be
medical or surgical. Medical management includes the use of steroids and cytotoxic agents. Cyclophosphamide, in
particular, is a favored therapeutic agent in this regard. Antibiotics have no proven role in HSS while anticoagulants
and thombolytic agents are generally contraindicated due to an increased risk of fatal hemorrhage. However, their
use may be considered with great care under special circumstances, for instance, intracardiac thrombi or massive
pulmonary embolism. For cases of massive hemoptysis due to large pulmonary aneurysms or those with lesions
confined to one segment or one lung, lobectomy or pneumectomy can be carried out. However, surgical risks
merit serious consideration and must be discussed with the patient. Transcatheter arterial embolization has
emerged as a less invasive alternative to surgery in selected cases of HSS. Overall, patients with HSS have a poor
prognosis and aneurysmal rupture is the leading cause of death. However, early diagnosis and timely intervention
is crucial in improving the prognosis. There is a need to clearly elucidate the genetic, etiologic and pathologic
basis for HSS in the future. Although most of the evidence put forward to refute the role of an infectious agent in
the etiology and pathogenesis of HSS is based on negative blood and other body fluid cultures, more robust
objective assessment is needed through the use of electron microscopy or 16 sRNA studies. The development of
better therapeutic agents is also needed to address and prevent the serious consequences arising from pulmonary
arterial aneurysms seen in BD and HSS. Also, the issue of anticoagulation in these patients is challenging and
requires further deliberation.
Disease name and synonyms
Hughes-Stovin syndrome (HSS, ORPHA228116) was
named after two British physicians, Drs. John Patterson
Hughes and Peter George Ingle Stovin. They first
described the findings of the syndrome (deep venous
thrombosis and segmental pulmonary artery aneurysms)
in a total of four male patients with pulmonary artery
aneurysms in 1959 [1]. Two of these patients were their
own while the remaining two had been described pre-
viously in literature [2]. The syndrome has not been
referred to by any other synonym in medical literature.
Definition and diagnostic criteria
HSS is a rare disorder of unknown etiology. Although
the association between multiple pulmonary artery
aneurysms and venous thrombosis of the lower limbs
had been reported by Beattie and Hall in 1911, it was
not until 1962 that the eponym “Hughes-Stovin Syn-
drome” was formally introduced in medical literature for
HSS [2].
Being an extremely rare disease, there is no formally
described diagnostic criteria or pathognomonic laboratory
investigation for this syndrome. Generally, the syndrome
is characterized by the findings of thrombophlebitis and
multiple pulmonary and/or bronchial aneurysms [3]. One
other syndrome, Behcet’s disease (BD), is also associated
with this aneurysm-thrombosis combination.
Turkish venercologist Halushi Behcet described the
constellation of hypopyon, iritis and orogential ulcers in
1937 [4]. However, a decade earlier, Adamantiades had
reported the disease as well. Although this gave birth to
the eponym Adamantiades-Behcet’s disease [5-7], the
syndrome continues to be widely referred to as BD in* Correspondence: taimur@gmail.com
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medical literature. The acronym MAGIC describes the
features of “Mouth And Genital ulcers with Inflamed
Cartilage” seen in BD [7].
Therefore, if a patient presents with this set of find-
ings (aneurysms and thrombosis) and the clinician is
able to rule out other causes, then the patient either has
HSS or BD. However, BD can be ruled out if its other
distinctive features are absent in the patient. This is how
HSS has been diagnosed in the majority of the case
reports in literature.
Epidemiology
HSS is an exceedingly rare disorder with less than 40
published cases in English medical literature. For this
reason, its population-based incidence can’t be deter-
mined. It usually affects the young adult population
bracket (reported cases ranged in age from 12 to
48 years) and holds a strong predilection for the male
gender [8-10]. HSS does not appear to have preponder-
ance for any geographic location. Cases of HSS have
been reported from diverse geographical areas including
North America, Europe, Africa and Asia [11-14]. None
of the reports have mentioned consanguineous mar-
riages in the parents of the patients suffering from HSS.
Thus, the genetic basis and familial predisposition of
HSS remains nebulous.
Clinical description
About 25% of patients with HSS develop thromboembo-
lism, arterial aneurysms and vascular occlusions. The
distribution of the vascular component of the syndrome
is as follows: arterial (7%), venous (25%) or both (68%)
[15]. The clinical paradigm of HSS can be divided into
three phases [3,10]:
a. Symptoms of thrombophlebitis
b. Formation of large pulmonary and/or bronchial
aneurysms
c. Aneurysmal rupture leading to massive hemopty-
sis and death
These stages usually evolve successively. The first and
second phases have to be present for the diagnosis of
HSS while the third phase is the usual ultimate outcome
for untreated patients. The typical presenting features of
HSS are related to the presence of the pulmonary aneur-
ysms and peripheral venous thrombosis. These signs and
symptoms are listed in figure 1 [8,16-18]. Patients can
have seizures, diplopia and cephalalgia secondary to
raised intracranial pressure consequent to cerebral
venous sinus thrombosis [1,19]. The raised intracranial
pressure also accounts for the papilledema of the optic
disc observed in some patients with HSS [20].
Aneurysms observed in HSS maybe single, multiple,
unilateral or bilateral [15]. These aneurysms generally
involve the pulmonary and bronchial arteries but can
also occur anywhere in systemic circulation. For exam-
ple, Herb et al have reported HSS in a patient who had
an aneurysm of the left hepatic artery [21]. Similarly,
aneurysms in the iliac artery have also been described
[20]. The low-pressure aneurysms are usually benign
with a minimal risk for vessel dissection or rupture [22].
Even in the cases of large dilatations with diameters up
to 16 cm, this risk remains low as long as the vascular
pressures remain within control. On the other hand,
high pressure aneurysms are associated with serious
morbidity and mortality [23].
Recurrent phlebitis frequently involves the large ves-
sels resulting in thromboembolism, with even reports
of thrombosis of the vena cava, cardiac chambers,
jugular vein, iliac vein, femoral vein and dural sinuses
[8,10,16,19,24-27]. Patients with thrombosis in the
vena cava may have engorged abdominal superficial
veins [26].
Etiology and pathogenesis
The exact etiology and pathogenesis of HSS is currently
unknown. Several proposed theories have attempted to
explain the manifestations of this rare entity [16,28].
The current consensus is that vasculitis is the primary
pathologic process underlying HSS [8].
1. Infections
Septic embolisms and abscesses have been proposed as
the cause of pulmonary aneurysms by some authorities
[3,29-31]. In support of this theory, pulmonary aneur-
ysms have been preceded by infections in some cases,
including scrotal abscesses [1,29], epididymitis [2] and
oophoritis [32]. Venous thrombosis can also be consid-
ered to arise as a consequence of septic emboli, bacterial
toxins or hyperergic reactions [33].
However, infectious agents, as an etiology for HSS, have
generally received less attention due to two reasons.
Firstly, various antibiotic regimens that have been tried in
the treatment of HSS have proven ineffective. Secondly,
there has been a lack of positive blood cultures in the eva-
luation of patients with HSS [1-3,11,29,31,32,34,35]. Cul-
tures of other body fluids in patients have also been found
to be sterile [2]. Nevertheless, the possibility of undetected
organisms of low-grade virulence has been speculated
[12]. According to the initial hypothesis [1], pulmonary
artery aneurysms may develop from a degenerative defect
in the bronchial arteries or may even be mycotic in origin
resulting from emboli infected with low-grade virulence
organisms. However, subsequent studies have failed to
find such comparable defects in the bronchial arteries.
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For BD, the following infectious agents have been
implicated in the pathogenesis but never conclusively
proven: Hepatitis A, B, C, E viruses, Herpes Simplex
Virus (HSV), Parvovirus B19, Helicobacter pylori, Chla-
mydia pneumoniae, Streptococcus sanguis, Streptococcus
mitis, Streptococcus salivarius and Saccharomyces cerevi-
siae [36]. The details for these agents in the pathogen-
esis of BD have been given in table 1. Interestingly, in
support of the infectious etiology of BD, it has been sug-
gested that proximity to the Silk Road and interactive
trade activities may have provided the necessary bridge
for the extension of the disease between the Mediterra-
nean and the East [5].
2. Angiodysplasia
Angiodysplasia of bronchial arteries is another debatable
hypothesis to account for the vascular changes [16,28,37].
Hughes and Stovin suggested that the structural changes
in the bronchial arteries impaired the provision of ade-
quate nutrition to the pulmonary arteries through the vasa
vasorum. In turn, these events led to inflammation,
damage to the elastic tissue and creation of arterial aneur-
ysms [21]. Conversely, it has been suggested that the
occlusion of the pulmonary arteries causes increased flow
and pressure in the bronchial arteries which predisposes
to the formation of bronchial artery aneurysms [21].
3. Possible manifestation of Behcet’s Syndrome
Some authors have suggested that HSS may actually be
a partially manifested BD owing to their similar findings
instead of a novel syndrome [16,19,38,39]. In fact, HSS
and BD are the only vasculitides associated with the
development of pulmonary artery aneurysms [4,40,41].
HSS has been variably described as “the cardiovascular
manifestation of Behcet’s disease” [14], “incomplete Beh-
cet’s” [19] and “a rare case of Behcet’s disease” [42] in
literature.
4. Mechanism of Thrombosis
The pathogenesis of thrombosis remains unclear in both
HSS and BD. Thrombophilia is not believed to be a
major contributory factor to the development of throm-
bosis in these patients [15]. Possible mechanisms to
explain the prothrombotic nature of BD in literature
include: progressive decline in endothelial progenitor
cells, direct endothelial injury, aberrant fibrinogenolysis
and platelet activity, abnormal levels and expression of
thrombomodulin, adrenomodulin and vascular endothe-
lial growth factor (VEGF), E-selectin activation and vari-
able nitric oxide levels [5,36]. Some reports have also
described the contribution of prothrombin gene muta-
tions and aberrant protein C levels and activity in the
thrombotic events of BD [43,44].
Figure 1 Signs and symptoms of Hughes-Stovin Syndrome.
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The presence of hyperhomocyteinemia independently
adds to the risk of venous thromboembolism in HSS.
Homocysteine causes thrombosis through multiple
mechanisms including the activation of platelets,
increased thrombin formation, impairment of fibrinoly-
sis and endothelial dysfunction through lipid peroxida-
tion and endothelial injury [45].
An important detail that merits consideration here is
that the clot in the pulmonary arteries in HSS or BD
arises mostly due to the arterial vasculitis rather than
venous thromboembolism, especially in patients without
deep venous thrombosis. Also, the thrombin in the lower
extremities is tightly adherent to the inflamed veins in
BD and HSS patients [12,19,37]. Balci et al [20] have
reported the case of a patient in whom the pulmonary
emboli recurred despite the placement of the Greenfield
filter. Although the event can simply be attributed to the
failure of the Greenfield filter, the possibility of the in
situ formation of the pulmonary embolus as a separate
entity from the deep venous thrombus can’t be ignored.
5. Extrapolation of the pathologic model for Behcet’s
disease
As mentioned earlier, although the exact pathologic
basis for HSS is unclear, it may be similar to the model
for BD as the two conditions share many features. Inter-
play of multiple factors such as genetic, environmental,
immunological and endothelial is most likely to be
involved in the pathogenesis of BD [36].
Strictly speaking, BD is not considered an autoimmune
disease [36] because of the following reasons: a) B-cell
hyper-reactivity not noted, b) female predominance not
reported across the board, c) absence of Sjogren syn-
drome in patients with BD. However, immunologic
mechanisms, different from those in other autoimmune
diseases, are believed to be involved in the pathogenesis
of BD. A growing body of evidence is suggestive of the
active role of T-cell mediated immune mechanisms and
responses in BD. In particular, gδ+T-cells are thought to
be involved in BD and their stimulation results from
microbial antigens produced by the oral flora [36]. The
exact role and interactions of CD4+ T-cells and its sub-
sets, CD8+ T-cells, double negative T-cells and other
antigen presenting cells (APCs) in BD are also being
investigated. In addition, neutrophil hyperactivation, a
key component of inflammatory vasculitis seen in BD,
occurs secondary to the release of the battery of cyto-
kines from the APCs and T-cells. Neutrophils exhibit
increased generation of reactive oxygen species (ROS),
phagocytic capacity and cytokine production as well
[5,36].
The main players of the cytokine axis active in BD
include interferon-g, IL-1b, IL-6, IL-8, IL-12, IL-18 and
TNF-a [5,36]. A role of autoantibodies in the expression
and manifestations of BD has also been proposed (table 2)
[5,36].
6. Bridge to immunogenetics
Classically and most convincingly, the association of BD
has been described with the human leukocyte antigen
(HLA) B51 in literature. In a recent met-analysis/sys-
tematic review comprising 4,800 cases and 16,289
Table 1 Infectious agents implicated in the pathogenesis of Behcet’s disease (adapted from Mendoza-Pinto et al [5]
and Kapsimali et al [36])
Agent(s) Pertinent rationale or refutation for involvement in Behcet’s disease
Hepatitis A, B, C, E viruses - Serological evidence of previous HAV, HCV and HEV infections not significantly different in patients
with Behcet’s disease as compared to controls.
- Previous HBV infection, however, seen in a significantly lower number of patients with Behcet’s
disease as compared with healthy controls.
Herpes simplex virus (HSV) Anti-HSV-1 antibodies observed more commonly in patients with Behcet’s disease than controls.
-DNA of HSV detectable in genital and intestinal ulcers but not in oral aphthous ulcers.
Parovirus B19 Parvovirus B19 IgG antibodies reported more in patients with Behcet’s disease as compared to
controls.
Helicobacter pylori Almost equal proportion of patients with Behcet’s disease and controls had H. pylori infection
following eradication therapy.
Chlamydia pneumoniae - IgG seropositivity for C. pneumoniae between cases and controls not significantly different.
- However, proportion of seropositive cases with higher IgG titres was greater.
Streptococcus sanguis, Streptococcus mitis and
Streptococcus salivarius
- Attenuation of skin and arthritic involvement in Behcet’s disease after antibiotic administration.
- Hypersensitivity to cutaneous streptococcal antigens reported.
- Aggravation of symptoms after dental manipulations.
- Treatment of chronic oral infections impacts long term prognosis of disease positively.
Saccharomyces cerevisiae Unclear role, distribution and pathogenetic relationship of ASCA antibodies in patients with Behcet’s
disease.
Heat shock proteins - Role for heat shock proteins of mycobacteria and streptococci suggested in Behcet’s disease.
- Model of molecular mimicry thought to be responsible for manifestations of Behcet’s disease.
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controls, the pooled odd’s ratio for the susceptibility to
BD associated with HLA-B51/B5 carriage was 5.78 (95%
CI: 5.00 - 6.67). The population-attributable risk (PAR)
of HLA-B51/B5 in relation to BD was 32% (Northern/
Eastern Europe) to 52% (Southern Europe). This study
also showed that the random-effects pooled prevalence
for HLA-B51/B5 was 57.2% (95% CI: 53.4 - 60.9%) in
cases of BD versus 18.1% (95% CI: 16.1 - 20.3%) in con-
trols [46]. It is speculated that HLA-B51 forms an inte-
gral part of an immunologic axis in patients with BD
that interacts with cross-reacting self-antigens and
immunoglobulin-like receptors on immune cells of the
body [36]. However, it is still unclear whether the strong
association of BD with HLA-B51/B5 is representative of
a true causal association or demonstrates linkage dise-
quilibrium with another gene that is operational in BD
[46].
In addition to the strong association of BD with
alleles of the major histocomptability complex (MHC),
recent studies have also highlighted the polygenic status
of BD and investigated the role of additional genes in
BD including, but not limited to MIC, MEFV, TNF,
HSP etc [5,36].
In contrast, out of all the literature reviewed, only one
report described the testing of a patient with HSS [13]
for HLA-B51. The latter was found positive in this
patient. However, the trend obviously needs to be con-
firmed in other patients before deriving any conclusions.
Also, it is not known whether patients in other reports
on HSS were tested for HLA-B51 or not as no specific
comment regarding such testing was made or alluded to
in those reports.
Diagnostic considerations
The diagnosis of HSS can be difficult owing to a non-
specific set of findings.
1. Laboratory findings
The laboratory findings in HSS patients are non-specific.
The patients can have leukocytosis, anemia, raised ery-
throcyte sedimentation rate (ESR) and elevated C-
reactive protein (CRP). Authors have also used the fol-
lowing tests in their assessment of HSS patients at initial
presentation to rule out a battery of competing diagno-
sis: coagulation studies, anti-nuclear antibody, rheuma-
toid factor (RF), serum complement levels (C3 and C4),
anti-double stranded DNA antibody, anti-neutrophil
cytoplasmic antibodies (c-ANCA and p-ANCA), anti-
cardiolipin antibodies, antistreptolysin O titres, hepatitis
viral serology, hemoglobin electrophoresis, examination
of bronchial washings, serological tests for detecting
infection by Treponema pallidum and HIV and bone
marrow biopsy [2,8,15,21,28,38,41,45].
2. Bronchoscopy
Bronchoscopy is often done in HSS patients who pre-
sent with hemoptysis. In patients with bronchial artery
aneurysms, fibre bronchoscopy can show pulsatile
tumor(s) with fibrinoid onlayers and/or ectatic vessels
[21] or bronchial obstruction caused by submucosal
mass [38].
3. Ventilation-perfusion (V-Q) scan
Patients with HSS can develop pulmonary embolism.
The formation of these emboli has been attributed to
the inflammatory response of the endothelial cells lining
the vessels [26]. The V-Q scan in such patients shows
area(s) with ventilation-perfusion mismatch.
4. Doppler ultrasound of extremities
Peripheral venous thrombosis is an important part of
HSS. Color Doppler examination of the extremities
should, therefore, be undertaken to evaluate the pre-
sence of deep venous thrombosis on the basis of reason-
able clinical suspicion.
5. Radiological diagnosis
a. Chest roentograms
Chest roentgograms (figure 2 and 3) depict pulmonary
artery aneurysms as hilar enlargements or round, lobu-
lated opacities [47].
b. Conventional angiography
Traditionally, conventional angiography (figure 4) has
been regarded as a gold standard for the diagnosis of pul-
monary artery aneurysms. It also aids in assessment of
angiodysplastic bronchial arteries in HSS. The character-
istic picture seen is aneurysmal formation proximal to
the occluded segments while distal to the interruption,
signs of hypoperfusion are observed [48]. However, it
should be noted that selective pulmonary angiography
can be hazardous as it carries the risk of aneurysm
rupture [17].
c. Helical computed tomography
However, it may not be possible to perform angiography
in all patients; especially in patients with thromboses in
Table 2 Autoantibodies proposed to be involved in
pathogenesis of Behcet’s disease (adapted from
Mendoza-Pinto et al [5] and Kapsimali et al [36])
# Autoantibody
1. Anti-endothelial antibody (a-Enolase autoantibody)
2. Antineutrophilic cytoplasmic antibody (ANCA)
3. Anticardiolipin antibody
4. Autoantibody to Retinal S antigen
5. a-Tropomyosin autoantibody
6. Kinectin autoantibody
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the vena cava which limit the passage of the catheter
[26]. In such cases, other non-invasive modalities such
as helical computed tomography (CT) may demonstrate
high quality vascular images with minimal amount of
contrast material used (figure 5). In fact, multi-detector
row helical CT angiography now offers more precise
visualization of large systemic arteries than does conven-
tional angiography. As such, it can be regarded as an
emerging and effective standard in the diagnosis of pul-
monary artery aneurysms because of its non-invasive
nature, ease of performance and increasing availability.
Furthermore, Ketchum et al showed that 3D volume
rendering analysis can detect morphologically abnormal,
tortuous branches of bronchial arteries even before
aneurysm formation [12,49]. Mahlo et al [17] and Herb
et al [21] recorded distorted and dilated bronchial
arteries with convoluted small branches when they per-
formed digital subtraction angiography of the bronchial
arteries.
d. Magnetic resonance angiography
Magnetic resonance angiography (MRA) is relatively less
sensitive than helical CT for picking up small aneurysms
[20,26,47,49].
Figure 3 CT scan of the chest showing ill defined infiltrate in
lower lobe of the right lung. Reproduced with permission from
Al-Jahdali H [15].
Figure 2 X-ray of the chest showing an infiltrate in the lower
lobe of the right lung. Reproduced with permission from Al-
Jahdali H [15]
Figure 4 Pulmonary angiography showing an aneurysm of the
interlobar pulmonary artery. Reproduced with permission from Al-
Jahdali H [15].
Figure 5 Contrast enhanced CT scan of chest showing
pulmonary artery aneurysm. Reproduced with permission from
Al-Jahdali H [15].
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6. Histological diagnosis
Classic histopathologic findings of HSS [1,2] include dif-
fuse dilatation and partial occlusion of the aneurysmal
arteries, perivascular infiltration that is predominantly
lympho-monocytic and diffuse proliferative sclerosis. The
elastic and muscular fibers become annihilated whereas
tunica media is completely filled with lymphocytes,
plasma cells and foam cells in the affected vessels. The
perivascular infiltrate extends into the adventia and into
the overlying thrombus. Macrophages containing hemo-
siderin may also be observed. In the pulmonary veins,
fibrosis and muscular medial thickening is seen. How-
ever, Durieux et al [37] described a dense neutrophilic
infiltrate in the walls of the vessels in HSS. On the other
hand, Meireles et al [35] reported the histologic findings
of HSS in a patient’s necropsy as medial hypertrophy,
intimal fibrosis with marked eosinophilic infiltrates.
In comparison, the histology of vascular lesions in BD
is characterized by a triad of “neutrophilic infiltration”,
“endothelial cell swelling” and “fibrinoid necrosis” [5].
Similarly, neutrophils establish an early presence in the
mucocutaneous and ocular lesions of BD [5].
The pulmonary arteries showed widespread lesions of
Regardless of the modality used, a complete visualization
of prominent bronchial arteries and pathologic enhance-
ment of pulmonary thromboembolism should alert phy-
sicians to the suspicion of pulmonary vasculitis. A
timely diagnosis and intervention is imperative to pre-
vent potentially life-threatening massive hemorrhage due
to pulmonary aneurysms [12].
Differential diagnosis
Amongst the causes for pulmonary artery aneurysm
(table 3) [50], there are two idiopathic, albeit similar,
syndromes that are associated with thrombosis: BD and
HSS. There exists a significant overlap between the clin-
ical, radiological and histopathological findings of HSS
and BD (table 4). Specifically, pulmonary involvement is
often indistinguishable between the two entities. How-
ever, whether the two conditions are identical is open to
both debate and speculation as the exact pathophysiol-
ogy of both syndromes remains unclear.
The target populations as well as the pulmonary mani-
festations in BD appear to be similar to that in HSS
(table 4). Also, both diseases are characterized histologi-
cally by the destruction of the vessel walls of pulmonary
vasculature along with perivascular infiltration [37,50].
BD primarily affects young adults, especially males
[40,41,51]. However, this gender distribution is not uni-
versal. There are also studies which have shown a female
preponderance [52,53]. This is in contrast to HSS where
the majority of the cases (>80 - 90%) have been seen in
male population. Although BD is found all over the
world, certain regions like Far East, the Mediterranean
(the ancient “Silk Road”) and the Middle East have
reported higher rates of prevalence [36,40,41,51,54]. BD
has been known to occur more commonly in geographic
areas that fall between latitudes 30 and 45 degrees north
[7]. The incidence of BD in different regions is as follows:
North America and Europe - 0.38 - 7.5/100,000 and
Turkey - upto 42/100,000 [36].
Findings unique to BD are recurrent genital ulceration,
eye lesions, skin lesions, iritis, arthralgia and a positive
pathergy test [40,55,56] and this helps in distinguishing
the two entities. For the clinical diagnosis of BD, the
patient must have recurrent oral ulceration with atleast
two of the following clinical manifestations: recurrent gen-
ital ulceration, skin lesions, eye lesions or a positive
pathergy test [57]. The pathergy test is performed by tak-
ing a sterile 20 - 22 gauge needle and obliquely piercing
the skin to a depth of 5 mm. If the site develops an erythe-
matous papule after 48 hours, the test is positive [5].
It is believed that the aneurysms seen in BD arise
either due to the process of obliterative endarteritis of
the vasa vasorum or they are pseudo-aneurysms charac-
terized by edematous vessel walls. The latter are usually
formed after perforation [38].
Management
Owing to the lack of controlled trials, there are no stan-
dard treatment guidelines for the management of HSS.
As BD and HSS share certain clinical characteristics and
Table 3 Causes for pulmonary artery aneurysms without
arteriovenous communication (adapted from Fischer et al
[18])
1. Infection
Tuberculosis (Rasmussen’s aneurysms)
Syphilitic
Other (bacterial and fungal); may arise from right sided endocarditis
2. Structural cardiac abnormalities
Congenital heart disease
Acquired cardiac abnormalities
Structural vascular abnormalities
Congenital
Cystic medionecrosis/atherosclerosis
Acquired
Marfan’s syndrome
Behçet’s disease
3. Pulmonary hypertension
4. Idiopathic vasculitic syndromes
Hughes-Stovin syndrome
Behçet’s disease
5. Trauma (for example, from a Swan-Ganz catheter)
6. Miscellaneous
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manifestations, the management of HSS can be tailored
along the lines of BD [19]. Despite this, it should be
noted that the European League Against Rheumatism
(EULAR) has acknowledged the need for properly
designed and robust prospective studies for improving
management strategies even for BD [58,59]. In this sec-
tion, relevant EULAR recommendations with regards to
the management of BD disease have been referred to,
especially with regards to vascular disease.
1. Medical management
a. Immunosuppressive therapy
Most commonly, immunosuppressive therapy involving
a combination regimen of glucocorticoids and cyclopho-
sphamide has been employed as a first line medical
management in the treatment of HSS, although its effec-
tiveness remains to be fully established [8,40]. The ster-
oids are usually administered as pulse IV therapy
followed by oral steroids usually with subsequent taper
[15,19,38,45]. Depending upon the clinical response,
steroids can be discontinued but cyclophosphamide is
usually given for at least one year after complete remis-
sion [4]. One described regimen for the treatment of
arterial aneurysms is monthly pulses of cyclophospha-
mide (1 gram) plus prednisolone (1 mg/kg/day). The lat-
ter is then tapered over the course of several months to
a dose less than 30 mg/day [60].
Immunosuppression has the potential to stabilize
small aneurysms in the pulmonary vasculature [8], and
in some cases can even make them regress [27]. Other
agents that have been variably used in the treatment of
HSS include colcichine, cyclosporine and azathioprine
[8,15,38]. However, despite the favorable response seen
in some cases, the caveat that needs to be remembered
is that immunosuppressive therapy may not always be
helpful in the cessation of disease progression especially
if the disease has already evolved to an advanced stage
[61].
EULAR recommends the use of steroids, azathioprine,
cyclophosphamide or cyclosporine A for the management
of acute deep vein thrombosis of BD while cyclophospha-
mide and corticosteroids have been recommended for pul-
monary and peripheral arterial aneurysms in BD [58]. For
pulmonary aneurysms, EULAR has recommended the
continued use of cyclophosphamide for two years followed
by azathioprine [58]. Cyclosporine A, being neurotoxic,
should not be used in patients with neurological manifes-
tations of BD [58].
b. Antibiotics
Antibiotics have no proven role in the management of
HSS [1,2,29,34].
c. Anticoagulants and thrombolytic agents
Anticoagulants and thombolytic agents are generally
considered contraindicated due to an increased risk of
fatal hemorrhage, even though they confer a beneficial
effect in an embolic state [37]. Some patients with HSS
already have hemoptysis at initial presentation; making
these agents an unsafe therapeutic option. This places
physicians on the horns of a dilemma because of the
pro-thrombotic nature of the syndrome and the occur-
rence of potentially life-threatening events such as intra-
cardiac thrombi or pulmonary embolism. Therefore,
anticoagulation may be employed with great vigilance in
a few carefully evaluated circumstances where the bene-
fits are believed to significantly outweigh the risks. Kim
et al successfully used anticoagulation in a patient with
HSS, hyperhomocysteinemia and intracardiac thrombi
employing warfarin with enoxaparin as a bridge [45].
Tsai et al have recommended that in patients with pul-
monary embolism and HSS, anticoagulation should be
used very judiciously. This is only in patients with
embolisms in the main pulmonary artery that lead to
life-threatening clinical deterioration and hemodynamic
instability [26]. Anticoagulation maybe used to prevent
or treat deep vein thrombosis after the pulmonary artery
aneurysms have been surgically resected [15] or after
adequate immunosuppressive treatment has been given
[40]. This is usually achieved by starting the patient on
intravenous or subcutaneous heparin and then shifting
to oral warfarin therapy. However, the caveat here is
that patients may still develop thrombosis despite ade-
quate anticoagulation [38]. Another point to consider is
the possible role of deep venous thrombi in aneurysm
formation. By that logic, long term anticoagulation may
have the potential to prevent further aneurysm forma-
tion by targeting this particular mechanism [62].
Table 4 Similarities in pulmonary involvement between Behcet’s disease and HSS (adapted from Erkan et al [38])
Characteristic Details
Gender Predominantly young males
Triad of clinical findings Fever, arthalgias, thrombosis
Occurrence of thrombosis with pulmonary artery aneurysms HSS - 100%; Behcet’s disease - 80%
Overlapping histopathologic features Destruction of arterial walls, perivascular infiltrates
Therapy Cytotoxic drugs and corticosteroids
Most common cause of death Rupture of pulmonary artery aneurysm
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The issue of anticoagulation in patients with HSS
and BD is obviously complex and requires focused stu-
dies before any definite recommendation can be made.
EULAR has stressed the need for controlled trials to
evaluate the utility of anticoagulation in patients with
BD. The use of anticoagulants and antifibrinolytic
agents in BD is not currently recommended by EULAR
[58].
d. Antiplatelet agents
In the absence of extensive thrombi, some authors have
suggested the use of antiplatelet agents such as low dose
aspirin in patients [63,64]. However, EULAR doesn’t
currently recommend the use of antiplatelet agents in
BD [58].
e. Ventilator support
Patients presenting with severe hemoptysis may require
initiation of mechanical ventilator support [65].
f. Surgical consultation
Along with the initiation of medical management, an
urgent consultation should be given to the cardiothor-
acic surgery team, especially if the patient presents with
severe or recalcitrant hemoptysis [26].
2. Surgical management
For the cases of massive hemoptysis due to large pul-
monary aneurysms or those with lesions confined to
one segment or one lung, lobectomy or pneumectomy
can be carried out to remove the aneurysms based on
the data from published case reports. Kindermann et al
have described the resection of pulmonary artery aneur-
ysm with the reconstruction of the arterial segment
using a saphenous vein grafts [66]. Durieux et al [37]
used surgical intervention for three cases of HSS who
had isolated pulmonary aneurysms and none of them
showed any signs of recurrence on subsequent follow
ups. However, this is not the case for most patients of
HSS where bilateral, extensive pulmonary aneurysms
limit the role of surgery as the frontline treatment mod-
ality. Furthermore, high operative morbidity and mortal-
ity associated with surgery is another consideration that
must be discussed with patients [1,2,66,67]. Additionally,
after surgery, there is a 25% risk of recurrence of aneur-
ysms at the site of anastomosis [68].
For BD, Alexoudi et al have recommended that surgery
be considered as a treatment of choice for vascular invol-
vement in the following circumstances: expanding aneur-
ysm, acute rupture and severe ischemia [69]. However,
surgeons should be aware of the possibility of the forma-
tion of pseudoaneurysms (if arterial involvement) and
false anastomotic aneurysms (if venous involvement)
after surgical intervention. The pre-operative use of dox-
ycycline has been recommended because of its potential
role in off-setting these deleterious post-operative events
[69].
3. Transcatheter arterial embolization
For patients who are not suitable candidates for aggres-
sive surgical intervention, transcatheter arterial emboli-
zation, being a less invasive procedure, offers a suitable
and effective alternative in HSS [8]. Furthermore, since
aneurysms in HSS are usually bilateral and multifocal at
the time of diagnosis, embolization is a preferred modal-
ity in such patients [8]. Arterial embolization is also an
acceptable therapeutic option in patients with severe or
recurrent hemoptysis [21]. Authors have performed
embolization with several agents including steel coils,
ethibloc and an epoxy, isobutyl cyanoacrylate [8]. Asso-
ciated complications of arterial embolization include
arteriovenous fistulae, pulmonary infarction, abscess for-
mation, oesophageal necrosis, bronchial necrosis, and
spinal ischemia [70,71]. Rarely, the patients may require
repeat embolization because the arterial lesions may
become recanalized or revascularized [21]. Balloon veno-
plasty may be used in patients with vena caval thrombo-
sis. However, it is only safe to perform this procedure in
the early stages [72].
Prognosis
Aneurysms of arterial origin portend a poorer prognosti-
cation than venular aneurysms [15]. In particular, pul-
monary artery aneurysms have a poor prognosis.
Hemoptysis can arise from three mechanisms in
patients:
1. Aneurysmal rupture; it is the leading cause of
death in patients of HSS. The erosion of the rup-
tured aneurysm into a bronchus leads to hemoptysis
[73].
2. Active vasculitis that can lead to thrombosis [73].
3. Bronchial artery hypertrophy secondary to ische-
mia that, in turn, has been attributed to the pulmon-
ary artery occlusion [21]. Mahlo et al. speculated
that the cause of death in HSS could be due to the
rupture of angiodysplastic bronchial arteries rather
than rupture of aneurysmal pulmonary arteries [17].
Early diagnosis and timely intervention is, therefore,
crucial in improving the prognosis of patients with HSS.
Appropriate treatment, if instituted promptly and early
in the course of the disease, has the potential to induce
remission [4,40,47,54,74].
Future directions
There is a lack of clear diagnostic criteria and manage-
ment guidelines for HSS. The disease is clearly a rare
but grave clinical entity and has not been extensively
studied so far. Most of the data on HSS is in the form
of sporadic case reports. Establishing diagnostic criteria
and formulating management guidelines for HSS is
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imperative to standardize the quality of care delivered
and to improve prognosis across the different geo-
graphic regions of the world since HSS is associated
with significant morbidity and mortality. There is also a
need to better elucidate the genetic basis and familial
preponderance, if any, of HSS. As with any genetic dis-
ease, knowledge of the latter will be helpful to clinicians
in the provision of pre-conception genetic counseling to
patients with HSS.
Future investigations should include human leukocyte
antigen (HLA) typing in patients to compare and contrast
the genetic basis of HSS with BD. Although it should be
acknowledged that HSS and BD share many clinical, radi-
ological and histological features, the suggestion that they
are, in essence, the same disease can neither be currently
accepted nor categorically refuted because the pathologic,
genetic and etiologic basis of both conditions has not
been clearly unraveled. These aspects have been high-
lighted for focused research in the future. Unless these
arenas are elucidated, the “pathogenic kinship” between
the two conditions remains obscure [18] and should be
examined with scientific skepticism and perspicacity.
Although most of the evidence put forward to refute the
role of an infectious agent in the etiology and pathogen-
esis of HSS is based on negative blood and other body
fluid cultures, more robust objective assessment is clearly
needed through the use of electron microscopy or 16
sRNA studies. Finally, the development of better thera-
peutic agents is needed to address and prevent the ser-
ious consequences arising from pulmonary arterial
aneurysms seen in BD and HSS. Also, the issue of antic-
oagulation in these patients is challenging and requires
further deliberation.
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